Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Maybe next month.
Yep, maybe tomorrow...................................;-)
Still awaiting news from the New CEO , MM
Can’t be much longer ...I hope
https://twitter.com/robclarkelab?lang=en
Rob Clarke Retweeted
Mcr Breast Centre
@MCRBreastCentre
·
26m
To mark #BreastCancerAwarenessMonth, and #wearitpink day this Friday we are hosting a public awareness session to share the latest scientific highlights with the public.
This event will focus on how to reduce the risk of breast cancer. Register at
https://eventbrite.com/e/how-can-we-predict-and-prevent-breast-cancer-now-public-outreach-event-tickets-116611657607
Who will be speaking?
Professor Rob Clarke, PhD Rob Clarke is a Professor of Breast Biology and Director of the Manchester Breast Centre, comprising 38 basic, translational and clinician scientists active in breast cancer research. His research investigations will lead to an increased understanding of the biology of the normal and malignant human breast which, in turn, could lead to the development of new strategies or new targets for prevention of primary and secondary breast cancer.
Dr. Jed W Fahey
@jedosan
A very interesting paper from a very competent team at Texas Tech and elsewhere. Putting together #sulforaphane, #mitochondrial dysfunction, #oxidative damage and #Nrf2.
Aging Highlights
@aginghighlights
· Oct 17
Sulforaphane prevents age-associated cardiac and muscular dysfunction through Nrf2 signaling in mice.
............................
ORIGINAL PAPER Open Access
Sulforaphane prevents age-associated cardiac and muscular dysfunction through Nrf2 signaling
First published: 17 October 2020
https://onlinelibrary.wiley.com/doi/full/10.1111/acel.13261
as the share accumulation continues...as it has done for months!!!???:-)
or push the Boom button.....Perfectly poised....Gl ;-)
Well we are waiting on the new CEO to turn the key here :-)
A/Prof Mansell said the discovery was like “finding how turning a key in a car ignition tells the engine to start producing energy to turn the wheels”.
The study found that a protein called STAT3 plays a critical role in communicating signals from surface sensors on the cell (macrophages) , to the cell’s engine room- the mitochondria – that a foreign invader has been identified.
This reprograms the mitochondria to kick-start energy production and usage to generate inflammation, said co-author Dr Dan Gough. “When an immune cell detects an infection, like bacteria, it rapidly changes its metabolism from a resting to an inflammatory state,” Dr Gough said.
“This provides the energy and building blocks to produce chemicals called cytokines, which fight off the infection. This metabolic or energetic ‘switch’ occurs in the engine room of cells – the mitochondria,” he said.
Hudson Institute Director, Professor Elizabeth Hartland said the discovery was pivotal to understanding how certain immune cells adapt their metabolic activity to drive inflammation.
“There has long been a gap in our knowledge of how macrophages take a signal from the cell surface and translate it to the mitochondria. Now, thanks to the work of our inflammation scientists at Hudson Institute, we have an answer to that question,” said Hudson Institute Director, Professor Elizabeth Hartland.
“This missing link is pivotal because it gives us a deep understanding of the signalling events in our immune system’s first line of defence – the inflammatory process. This discovery has big implications for further research into treatments for a wide range of inflammatory diseases.”
SFX-01 was selected for Covid-19 patient trials because it is a potent activator of the Nrf2 pathway which regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation, but SFX-01 is also a potent activator of the STAT3 pathway and the recent discovery that STAT3 is the "key to immune system inflammation" which must significantly increase SFX-01's potential and chances in becoming an effective treatment for multiple disease targets, including Covid-19.
STAT3 was the focus of SFX-01's phase 2 breast cancer trials, where results were outstanding and life changing for some patients, phase 2b patient trials are in the planning with Manchester University and news on their status is expected soon, and so given SFX-01's dual activation of these two key pathways and SFX-01's panacea potential, the interest from Big Pharma presumably must be highly significant, which can only add to the chances of an early JV commercil partnership and/or strategic investor imho.....Gla....News from the new CEO at anytime. ;-)
Health
October 1, 2020
Key to immune system inflammation discovered
Hudson Institute scientists have discovered the key to how cells turn on inflammation and fight infection, providing the knowledge to potentially reduce or stop destructive inflammation in future.
The finding comes as the world finds itself in the grip of the SARS-CoV-2 viral pandemic, where raging inflammation caused by the body’s overwhelming immune response in some individuals can lead to death and debilitating ongoing symptoms.
“Inflammation arising from our own immune system response is now recognised as an underlying component of almost every disease,” said A/Prof Ashley Mansell co-author of the study published in Nature Communication. “This includes heart, lung, brain and infectious diseases, cancer, diabetes and chronic kidney, liver and autoimmune diseases.
“If we could reduce dysfunctional or exaggerated inflammation, we would reduce the suffering associated with these severe inflammatory diseases.
“Understanding how cells turn on inflammation provides the building blocks to do this, by potentially targeting these pathways to restrain or stop inflammation attacking the body.”
Presumably no shortage of patients for SFX-01's Covid-19 patient trials, as SFX-01 will be administered to patients with pneumonia and acute respiratory infections regardless of testing positive for Covid-19 , and so early reporting could be very likely, and SFX-01's commercial potential could be huge if positive indications are observed. Gla ;-)
SFX-01 treatment for Acute Respiratory Infections (STAR-Covid19)
A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or confirmed SARS-CoV-2 infection
"for the avoidance of doubt, this trial permits inclusion of patients presenting with acute respiratory infections whether or not the test for SARS-CoV-2 is positive. Patients can be randomised to the study while awaiting the results of the test for SARS-CoV-2."
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003486-19/GB
Hardly surprising that SFX-01 will be administered to patients with pneumonia regardless of testing positive for Covid-19 or not....could be massive if proved effective. Gla ;-)
Nearly five times more people dying of flu and pneumonia than coronavirus
12 Aug 2020
Read more: https://metro.co.uk/2020/08/12/nearly-five-times-people-dying-flu-pneumonia-coronavirus-13118709/?ito=cbshare
2 x 250k trades just gone through at 14.03p...!!!!???? Gla ;-)
Accumulation on the cheap, as i can't see how they would be sells at that price and it was confirmed earlier on Advfn that all the 14p trades were buys!!!?????
courtesy of smackeraim;
I can get a quote for 150k at 14p.. those are buys..
http://prntscr.com/v2d0j9
Evgen initially stated that the Covid-19 trial would be conducted at up to 6 hospitals in Scotland and the North of England, although University of Dundee's press release stated "from hospitas across the UK" , and so maybe could include Bolton, or maybe even make SFX-01 available to her, given her high profile position....best wishes to her regardless.
16/6/20
The study will recruit up to 300 volunteers from hospitals across the UK, with patients offered the chance to participate immediately after their diagnosis. Half the group will receive SFX-01 in addition to standard hospital care while the other half will receive a placebo. Results are expected by the end of the year.
https://www.dundee.ac.uk/stories/clinical-trial-potential-covid-19-treatment
Yes wider field of patients than I first thought:
"for the avoidance of doubt, this trial permits inclusion of patients presenting with acute respiratory infections whether or not the test for SARS-CoV-2 is positive. Patients can be randomised to the study while awaiting the results of the test for SARS-CoV-2."
Don't know if Bolton is one of the trial sites but hopefully it is.
Could be offered SFX-01 as detailed on clinical trial link posted by Timbo earlier, whereby SFX-01 will be administered to patients with pneumonia regardless if they've tested positive for Covid-19 or not....and so high profile coverage possible if she makes speedy recovery. Gla and gl to her...:-)
Labour MP Yasmin Quereshi has been hospitalized after testing positive for the coronavirus.
UK Shadow International Development Minister Yasmin Qureshi has been admitted to hospital with pneumonia after testing positive for COVID-19.
The Labour member of parliament for Bolton South East said she had been self-isolating at home with her family.
Qureshi said in a statement that "I began to feel much worse and on Saturday I was admitted to the Royal Bolton Hospital with pneumonia."
It's also extremely interesting and exciting to note from the Cinical trial link that SFX 01 will be administered to patient with pneumonia regardless of being tested positive for Covid-19....SFX-01 was selected for Covid-19 patient trials because academia and industry believe , because of its potent Nrf2 activation, and anti-inflammatory properties, it beneficial in treating ARDS, acute respiratory distress syndrome, which as well as severe pneumonia is the reason Covid-19 can be so deadly and chronic for many. This means potentially, SFX-01 could be of benefit not only to Covid-19 but also ARDS and pneumonia, long after Covid-19 is hopefully defeated...and also suggests that early reporting on the trials would be highly likely if those with pneumonia are the focus....Gla ;-)
Let’s see if we get that RNS tomorrow :-)
We are up and running ..atb
Courtesy of timbo from Advfn....official confirmation of SFX-01's Covid-19 clinical patient trials....On and UP!!! ;-)
Here's the link to the protocol for the Dundee COVID study
https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003486-19/GB
I see the primary assessment is based on an ordinal scale and the main requirement for entry is pneumonia and a COVID test (which does not have to be positive)
It is Randomised placebo, controlled double, blind (all good) with 300 patients
If there's any substance behind the substantial share transfer/accumulation that appears to have been in progress over the last several months, then the amount of shares available in free float could be incredibly low imho.....and so any increased volume and demand for shares should see this fly....and long overdue as we continue to await an update on proceedings. Gl ;-)
Looking good and a very nice way to start a Monday morning......Excitement building!!! Gl ;-)
Let’s see if we get some next this week to break the 15 level and move up ....
Hope EVG starts to get the recognition it deserves. SFX-01 is a very promising candidate for the treatment of ARDS in COVID-19. Stuck on a very lowly market cap considering the huge potential and the backing of LifeArc.
Mm with you all the way.:)